Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Camsirubicin · GPX150

Small molecule · Inhibitor of DNA topoisomerase II (TOP2A) · developed by Monopar Therapeutics

Phase 1 Most advanced trial (none active)
MNPR Developer
1 Registered trials

What is Camsirubicin?

Camsirubicin is a synthetic non-cardiotoxic anthracycline analogue that intercalates DNA and inhibits topoisomerase II, inducing DNA breaks and activating tumor cell apoptosis. It is being studied in advanced soft-tissue sarcoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
GPX150
Drug type
Small molecule
Targets
DNA topoisomerase II (TOP2A)
Mechanism
Inhibitor of DNA topoisomerase II (TOP2A)
Pathways
DNA damage, apoptosis
Therapy area
Oncology
Developer
Monopar Therapeutics (MNPR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
VI79RD8VNN

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05043649 Phase 1 Advanced Soft-tissue Sarcoma Terminated MNPR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Soft-tissue Sarcoma

Other drugs acting on TOP2A

Doxorubicin FDA approved Amrubicin Phase 3 Berubicin Phase 2 IMX-110 Phase 1/2 Pegylated Liposomal Doxorubicin Phase 3

More from Monopar Therapeutics

Clonidine HCl Mucoadhesive Phase 2/3 MNPR-101-DFO*-89Zr Phase 1 MNPR-101-PCTA-177Lu Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the MNPR page.

Follow MNPR, the company behind Camsirubicin

See MNPR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MNPR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.